ArticleMolecular imaging and biology
Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC.
Article in Molecular imaging and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Laser-Ablated Gold Nanoparticles as Tunable Contrast Agents for Preclinical Imaging.Nanomaterials (Basel, Switzerland) · 2025Article
- Article
- First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies.International journal of radiation oncology, biology, physics · 2021Article
- PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT.Scientific reports · 2021Article
- Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography.iScience · 2019Article
- In Vivo Detection and Measurement of Aortic Aneurysm and Dissection in Mouse Models Using Microcomputed Tomography with Contrast Agent.Contrast media & molecular imaging · 2019Article
- Performance Evaluation of a Dedicated Preclinical PET/CT System for the Assessment of Mineralization Process in a Mouse Model of Atherosclerosis.Molecular imaging and biology · 2018Article
- ITIH5 mediates epigenetic reprogramming of breast cancer cells.Molecular cancer · 2017Article
- Contrast-enhanced micro-CT imaging in murine carotid arteries: a new protocol for computing wall shear stress.Biomedical engineering online · 2016Article
- Development of a methodology for in vivo follow-up of hepatocellular carcinoma in hepatocyte specific Trim24-null mice treated with myo-inositol trispyrophosphate.Journal of experimental & clinical cancer research : CR · 2016Article
- Multi-atlas registration and adaptive hexahedral voxel discretization for fast bioluminescence tomography.Biomedical optics express · 2016Article
- Biodistribution and Toxicity of X-Ray Iodinated Contrast Agent in Nano-emulsions in Function of Their Size.Pharmaceutical research · 2016Article
- In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography.Journal of visualized experiments : JoVE · 2016Article
- Synthesis of nanoparticle CT contrast agents:Science and technology of advanced materials · 2015Article
- Potential dual imaging nanoparticle: Gd2O3 nanoparticle.Scientific reports · 2015Article
- High-resolution 3D micro-CT imaging of breast microcalcifications: a preliminary analysis.BMC cancer · 2014Article
- Nanotechnology for computed tomography: a real potential recently disclosed.Pharmaceutical research · 2014Review
- Quantitative analysis of microscopic X-ray computed tomography imaging: Japanese quail embryonic soft tissues with iodine staining.Journal of anatomy · 2013Article
- Feasibility of sequential PET/MRI using a state-of-the-art small animal PET and a 1 T benchtop MRI.Molecular imaging and biology · 2013Article
- X-ray-computed tomography contrast agents.Chemical reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to compare the time-course of contrast-enhancement in spleen and liver using Exia 160 in comparison with Fenestra LC and VC in healthy mice. PROCEDURES: Healthy C57bl/6 mice were used in this study. Fenestra LC and VC was administered intravenously at a dose of 0.1 ml/20 g or 0.2 ml/20 g. Exia 160 at a dose of 0.05 ml/20 g or 0.1 ml/20 g. Each animal underwent a micro-CT scan before contrast injection (baseline) and immediately after contrast injection. Additional scans were performed at 1, 2, 3, 4, 24, and 48 h after contrast administration. The mice who received Exia 160 were also scanned after 15, 30, and 45 min.
resultsThe peak enhancement of Exia 160 occurred after 15 min for the spleen and after 30 min for the liver.
conclusionsExia 160 allows rapid spleen and liver enhancement. The high iodine content results in small injection volumes.
Indexed as
Identifiers
19067081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.